These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17618822)

  • 1. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
    Altundag K; Bulut N; Sari E; Harputluoglu H
    Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
    [No Abstract]   [Full Text] [Related]  

  • 2. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen, progesterone, and Her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer.
    Mavrova R; Radosa J; Schmitt K; Bohle RM; Rody A; Solomayer EF; Juhasz-Böess I
    Breast J; 2014; 20(3):322-4. PubMed ID: 24720257
    [No Abstract]   [Full Text] [Related]  

  • 4. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
    Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
    Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.
    Skalova A; Ryska A; Kajo K; Di Palma S; Kinkor Z; Michal M
    Histopathology; 2005 Jan; 46(1):43-9. PubMed ID: 15656885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
    Zhang B
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
    [No Abstract]   [Full Text] [Related]  

  • 7. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenge in the treatment of estrogen-receptor-negative ductal carcinoma in situ.
    Altundag K
    J Clin Oncol; 2005 Jul; 23(19):4469-70. PubMed ID: 15994163
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological characteristics of breast cancer.
    Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
    J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
    Millar EK; Tran K; Marr P; Graham PH
    Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changing behavior of estrogen and progesterone receptors with metastasis or recurrence of breast cancer].
    Morimoto K; Koh M; Yamamoto A; Tamura K; Yamamoto K; Yamamoto K; Suehiro S
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):925-9. PubMed ID: 16835481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab not for ductal carcinoma in situ?
    Nahleh Z; Namakydoust A; Bakkar R; Bishop J
    Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two score systems in Bcl-2 and Bax protein expression in invasive ductal carcinoma of breast and relation with oestrogen and progestrone receptors.
    Ayatollahi H; Ghaffarzadegan K; Sharifi N; Farahmand MJ; Jarafian AH
    Breast J; 2009; 15(3):310-2. PubMed ID: 19645793
    [No Abstract]   [Full Text] [Related]  

  • 18. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
    Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
    Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas.
    Frederik P; Cecile C; Tjalma WA
    Breast J; 2007; 13(4):436-7. PubMed ID: 17593058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.